# Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

> **NCT04240808** · PHASE1 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 10 (actual)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** UCD19 CAR T Cells

## Key facts

- **NCT ID:** NCT04240808
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-17
- **Primary completion:** 2023-03-24
- **Final completion:** 2023-10-23
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04240808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04240808, "Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04240808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*